WeVote
Log In

Bill

Bill

HB 7192

AN ACT IMPLEMENTING RECOMMENDATIONS OF THE BIPARTISAN DRUG TASK FORCE.

2025 Regular Session Introduced by Tim Ackert and 8 co-sponsors

Implements the Bipartisan Drug Task Force's recommendations to regulate PBMs, increase rebate transparency, strengthen drug supply-chain oversight, and protect consumers.

SIGNED BY GOVERNOR
#canada #consumerprotectiondepartment #contracts #drugwholesalers #drugs #electronicgovernmentinformation #emergencies #exportsandimports #healthcareproviders #healthinsurance #insurancedepartment #pharmacybenefitsmanagers #plans #rebates #reports #studies #taskforces #unfairordeceptivetradepractices #violations
0
WeVote Research Nonpartisan
Bill Summary · HB 7192

Summary — HB 7192: "An Act Implementing Recommendations of the Bipartisan Drug Task Force"

Status: Signed by Governor (Public Act No. 25-167) — Introduced: March 6, 2025 — Signed: July 8, 2025

Purpose / Intent

The bill implements recommendations produced by a state Bipartisan Drug Task Force intended to address prescription drug affordability, supply-chain resilience, market transparency, and consumer protections. Its overall goal is to reduce costs to patients and payers, curb unfair practices in pharmaceutical distribution and reimbursement, and strengthen the state’s ability to respond to drug shortages and emergencies.

Key topic areas addressed

The bill covers a broad set of topics reflected in its subjects. While the full text should be consulted for statutory detail, the legislation focuses on the following areas:

  • Pharmacy Benefit Managers (PBMs)

    • Increased oversight and regulation (registration, reporting, auditing).
    • Greater transparency of PBM practices (rebates, fees, “spread” pricing).
    • Contracting standards between PBMs, pharmacies and plans.

  • Rebates, Pricing and Insurance

    • Requirements for reporting drug rebates and how rebates are applied or passed through to consumers or plans.
    • Changes to insurer and plan obligations to disclose pharmacy benefit design and patient cost-sharing.

  • Drug Supply Chain, Wholesalers and Pharmacies

    • Enhanced licensing, tracking or accountability for drug wholesalers and distributors.
    • Measures to address shortages and emergency access to critical medications.

  • Drug Importation and Exports (Canada)

    • Provisions related to importation or procurement of drugs from Canada or other jurisdictions (subject to federal law and approval).

  • Consumer Protection and Unfair/Deceptive Practices

    • Expanded authority for the state Consumer Protection agency to enforce against deceptive practices by drug market participants.

  • Electronic Government Information, Reporting and Studies

    • Requirements for public reporting of pricing, rebate and market data; creation of databases or dashboards.
    • Ongoing studies, task force follow-ups or periodic reports to the legislature.

  • Health Care Providers and Insurance Department

    • New disclosure or administrative requirements for providers and insurers; regulatory roles and rulemaking authority for the Insurance Department and other state agencies.

Who is affected

  • Consumers and patients (potentially lower out‑of‑pocket costs, greater price transparency).
  • Health insurers and managed care plans (new reporting / compliance duties).
  • Pharmacy benefit managers, pharmacies (independent and chain), drug wholesalers and manufacturers (new regulation, licensing, or transparency obligations).
  • State agencies (Consumer Protection, Insurance Department, Health) — charged with implementation, enforcement and reporting.
  • Potential cross-border partners if drug importation provisions are included (e.g., Canada).

Procedural and timeline highlights

  • Introduced to the House on March 6, 2025; referred to Human Services, later to Insurance & Real Estate and Appropriations committees.
  • Committee reviews, public hearing March 11, 2025; multiple committee reports and LCO filings between March and May 2025.
  • House and Senate both passed the bill (with House Amendment Schedule A adopted and concurred by the Senate) on June 4, 2025.
  • Transmitted to the Secretary of the State June 27, 2025; signed by the Governor July 8, 2025 and enacted as Public Act 25-167.
  • Implementation may require agency rulemaking and further administrative steps; the final act will specify effective dates for particular sections.

Impact considerations and next steps

  • The act centralizes several long‑running policy responses to high drug prices: PBM oversight, rebate transparency, and supply chain measures. The practical effects (cost savings, market behavior) will depend on regulatory design and enforcement.
  • Agencies named in the act will likely issue regulations, guidance, and reports; fiscal impacts were considered by the Office of Fiscal Analysis during committee review.
  • For exact statutory language, effective dates, and section-by-section provisions, consult the final Public Act 25‑167 text available on the Connecticut General Assembly website or the Secretary of the State’s office.

Disclaimer: This summary is based on bill metadata and legislative history for HB 7192 (Public Act 25‑167) and the bill’s stated subject areas. For authoritative legal interpretation or application, refer to the enacted Public Act text and agency regulations.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.